Literature DB >> 20347549

Midterm results from a multicenter registry on the treatment of infrainguinal critical limb ischemia using a heparin-bonded ePTFE graft.

Raffaele Pulli1, Walter Dorigo, Patrizio Castelli, Vittorio Dorrucci, Fiore Ferilli, Giovanni De Blasis, Vincenzo Monaca, Enrico Vecchiati, Carlo Pratesi.   

Abstract

OBJECTIVES: To report midterm results of infrainguinal bypasses performed with a heparin-bonded expanded polytetrafluoroethylene (ePTFE) graft in patients presenting with critical limb ischemia.
METHODS: Over a 7-year period ending in 2008, 425 patients presenting with critical limb ischemia underwent infrainguinal revascularization using a heparin-bonded ePTFE graft in seven Italian vascular centers. Preoperative, intraoperative, and follow-up data were collected in a multicenter registry. Patients were predominantly male (79%) with a mean age of 73.5 years. Mean preoperative ankle brachial index (ABI) was 0.35 and 192 of the patients (45%) were diabetic. Intervention consisted of a femoral to below-knee bypass in 324 patients (76%), whereas the remaining 101 patients had a femoral to above-knee bypass. In patients with below-knee bypass, distal target vessels were the popliteal artery in 238 cases, the tibioperoneal trunk in 38 cases, and a tibial vessel in the remaining 48 cases (anterior tibial artery in 20 cases, posterior tibial artery in 23 cases, and peroneal artery in 5). Follow-up consisted of clinical and duplex scanning examinations within 3 months from the intervention and yearly thereafter. Early (<30 day) results were analyzed in terms of deaths, graft thromboses, and amputations with univariate and multivariate (stepwise logistic regression) analysis. Follow-up results were evaluated in terms of primary and secondary graft patency, limb salvage, and survival rate with univariate and multivariate (Cox regression) analysis.
RESULTS: Thirteen perioperative deaths occurred (3.1%). Thirty-day primary graft patency was 92.5% and limb salvage was 95.8%. Follow-up was available in 98% of patients with a median duration of 25.5 months (SD, 17.6; range, 1-72). Cumulative estimated 36-month primary and secondary patency, limb salvage, and survival rates were 61%, 70%, 83%, and 83%, respectively. At univariate analysis, the factors associated with poorer limb salvage rates during follow-up were the presence of ischemic ulcers or gangrene (log-rank, 8.4; P = .004; 95% confidence interval [CI] 1.2-3.5; odds ratio [OR], 2.1), the presence of only one patent tibial vessel (log-rank, 41.3; P < .001; 95% CI, 3.1-10.8, OR, 5.8), redo surgery (log-rank, 12.4; P < .001; 95% CI, 1.4-4; OR, 2.4) and the postoperative treatment with antiplatelet therapy in comparison to oral anticoagulants (log-rank, 5.1; P = .02; 95% CI, 1.0-3.4; OR, 1.8). At multivariate analysis redo surgery (P = .02; 95% CI, 1.1-3.1; OR, 1.8), poor runoff score (P < .001; 95% CI, 2.5-9.1; OR, 4.7) and preoperative clinical status (P = .02; 95% CI, 1.1-3.1; OR, 1.8) were independently associated with decreased limb salvage rates.
CONCLUSION: The use of a heparin-bonded ePTFE graft provides good early and midterm results, with low rates of late amputations. Primary and secondary patency made this graft an excellent alternative to autologous saphenous vein when it is absent, unsuitable, or of poor quality. Copyright (c) 2010 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20347549     DOI: 10.1016/j.jvs.2009.12.042

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  8 in total

Review 1.  Tissue Engineering at the Blood-Contacting Surface: A Review of Challenges and Strategies in Vascular Graft Development.

Authors:  Daniel Radke; Wenkai Jia; Dhavan Sharma; Kemin Fena; Guifang Wang; Jeremy Goldman; Feng Zhao
Journal:  Adv Healthc Mater       Date:  2018-05-07       Impact factor: 9.933

Review 2.  The role of infrainguinal bypass surgery in the endovascular era.

Authors:  Raffaele Pulli; Walter Dorigo; Azzurra Guidotti; Aaron Fargion; Alessandro Alessi Innocenti; Carlo Pratesi
Journal:  Ann Vasc Dis       Date:  2014-02-04

3.  A Multicenter Predictive Score for Amputation-Free Survival for Patients Operated on with an Heparin-Bonded ePTFE Graft for Critical Limb Ischemia.

Authors:  Walter Dorigo; Gabriele Piffaretti; Raffaele Pulli; Patrizio Castelli; Carlo Pratesi
Journal:  World J Surg       Date:  2017-01       Impact factor: 3.352

4.  SUrgical versus PERcutaneous Bypass: SUPERB-trial; Heparin-bonded endoluminal versus surgical femoro-popliteal bypass: study protocol for a randomized controlled trial.

Authors:  Mare M A Lensvelt; Suzanne Holewijn; Wilbert M Fritschy; Otmar R M Wikkeling; Laurens A van Walraven; Bas M Wallis de Vries; Clark J Zeebregts; Michel M P J Reijnen
Journal:  Trials       Date:  2011-07-18       Impact factor: 2.279

5.  Small caliber heparin loaded ultrafine microfiber woven graft achieved high patency rate in a preliminary study of canine carotid artery implantation.

Authors:  Masaki Fujita; Nobuaki Tanaka; Yuka Sakaguchi; Yosuke Takaya; Taisuke Kogawa; Hiroshi Tsuchikura; Tadahiro Sasajima; Kazuhiro Tanahashi
Journal:  JVS Vasc Sci       Date:  2020-07-14

6.  Gender-specific risk factors for peripheral artery disease in a voluntary screening population.

Authors:  Jade S Hiramoto; Ronit Katz; Steven Weisman; Michael Conte
Journal:  J Am Heart Assoc       Date:  2014-03-13       Impact factor: 5.501

7.  Tissue-Engineered Small Diameter Arterial Vascular Grafts from Cell-Free Nanofiber PCL/Chitosan Scaffolds in a Sheep Model.

Authors:  Takuma Fukunishi; Cameron A Best; Tadahisa Sugiura; Toshihiro Shoji; Tai Yi; Brooks Udelsman; Devan Ohst; Chin Siang Ong; Huaitao Zhang; Toshiharu Shinoka; Christopher K Breuer; Jed Johnson; Narutoshi Hibino
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

8.  Experimental comparative study of thrombogenicity of two differently luminal heparinized ePTFE vascular prosthetics.

Authors:  Mads Liisberg; Michael Stenger; Carsten Behr-Rasmussen; Jane Stubbe; Jes S Lindholt
Journal:  Ann Med Surg (Lond)       Date:  2018-09-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.